ImmunityBio: Pay

ImmunityBio paid its 4 named executives $30.0M in total in FY2025 (Dec). CEO Richard Adcock was paid $12.7M of that.

Pay$100 in the stock at the end of FY21 → $33
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Richard AdcockPresident and CEO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Patrick Soon-Shiong, M.D.Global Chief Scientific and Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
David SachsCFO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Regan LauerChief Accounting Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $11.1M. The CEO of ImmunityBio was paid $12.7M, 14% above the median.

  1. 1TG Therapeutics
  2. 2BridgeBio Pharma
  3. 3ImmunityBio
  4. 4Ultragenyx Pharmaceutical
  5. 5Immunocore Holdings
  6. 6Novavax
  7. 7Neurocrine Biosciences
  8. 8Allogene Therapeutics, Inc.Not disclosed
  9. 9Arcus Biosciences, Inc.Not disclosed
  10. 10Blueprint Medicines CorporationNot disclosed
  11. 11Fate Therapeutics, Inc.Not disclosed
  12. 12Kura Oncology, Inc.Not disclosed
  13. 13Syndax PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.